the Indian peptide drugs market is segmented into type and application. This market is expected to reach USD 883.0 million by 2022 from USD 381.8 million in 2016, at a CAGR of 15.0%. Increasing prevalence of chronic diseases such as cancer and diabetes and favorable government policies for the pharmaceutical sector are the major factors driving the growth of Indian peptide drugs market. For instance, according to GLOBOCAN, in 2015, the incidence of cancer (all types, excluding non-melanoma skin cancer) was 1.09 million in India. This is expected to reach 1.40 million by 2025. The availability of substitutes for peptide drugs may hinder market growth.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=77044734
Based on type, the Indian peptide drugs market is segmented into hormonal, antifungal, antibiotic, and ACE inhibitor. The hormonal segment is expected to register the highest CAGR during the forecast period. The rising incidences of diabetes, osteoporosis and cancer in India is the key factor driving the growth of this segment.
On the basis of application, the Indian peptide drugs market is segmented into diabetes, cancer, cardiovascular disease (CVD), gynecological application, infectious diseases, osteoporosis, and other applications (acromegaly, multiple sclerosis, and hepatitis). The diabetes application segment is projected to register the highest growth in this market due to the increasing prevalence and incidence of diabetes and rising awareness about the benefits of early diagnosis.
The Indian anticoagulant drugs market is also consolidated in nature. The Indian anticoagulant drugs market is dominated by Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (U.S.), Abbott Laboratories (U.S.), and Lupin Ltd. (India), which together held a share of 68.6% of the market in 2016. Other players in this market include Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd. (India), and VHB Lifesciences (India). These companies accounted for a combined share of 31.4% of the Indian anticoagulant drugs market in 2016.
